MuSCs, which are refractory to AAV transduction, express low levels of endogenous Aavr. Targeting muscle with AAV gene therapy is relevant for the treatment of inherited disorders of progressive muscular weakness, including Duchenne muscular dystrophy and spinal muscular atrophy. Here, KIAA0319L is linked to proximal spinal muscular atrophy.